DGAP-News: Keryx Biopharmaceuticals, Inc. Announces First Quarter 2014 Financial Results

        Print
| Source: EQS Group AG
DGAP-News: Keryx Biopharmaceuticals, Inc. /
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2014 Financial
Results

08.05.2014 / 13:00

---------------------------------------------------------------------

Keryx to Host Conference Call Today at 8:00 am ET

NEW YORK, 2014-05-08 13:00 CEST (GLOBE NEWSWIRE) --
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company
focused on bringing innovative therapies to market for patients suffering from
renal disease (the 'Company'), today announced its financial results for the
first quarter ended March 31, 2014. In the first quarter, Keryx raised
approximately $107.6 million, net of underwriting discounts and offering
expenses, through an underwritten public offering of common stock, ending the
quarter with $155.1 million of cash, cash equivalents, short-term investments
and interest receivable, and no debt. 

'Over the past few months we have made significant strides in expanding our
leadership team and building our commercial organization to support the launch
of Zerenex(tm), pending potential approval,' said Ron Bentsur, Chief Executive
Officer of Keryx. 'This work, along with the progress made on regulatory
filings and clinical development, bring us closer to potentially providing
Zerenex to patients in the U.S. and Europe.' 

Business Highlights

  -- Keryx has made significant progress preparing for the potential launch of
     Zerenex(tm) (ferric citrate coordination complex) in the U.S. With key
     strategic staff in place, the Company has opened an office in Boston, which
     will serve as the home base for its expanding commercial infrastructure.
     Among a host of activities, the Company is developing a brand plan,
     conducting market research, and determining sales force sizing and
     territory alignment to support the launch of Zerenex late in the third
     quarter, pending FDA approval.
  -- Important data related to Zerenex were presented in several posters and a
     late-breaking oral presentation at the National Kidney Foundation's Spring
     Clinical Meeting in Las Vegas in late April. The data included several
     analyses of the potential pharmacoeconomic benefits of Zerenex use in
     dialysis-dependent chronic kidney disease (CKD), if approved by the FDA, as
     well as efficacy and safety data from a phase 2 trial of Zerenex in
     non-dialysis dependent CKD patients.
  -- Outside of the U.S., progress was made on two important fronts:
     -- The European Medicines Agency (EMA) validated the Company's marketing
        authorization application (MAA), which seeks the approval of Zerenex as
        a treatment for hyperphosphatemia in patients with CKD, including both
        dialysis and non-dialysis dependent CKD. The review is ongoing and, if
        reviewed on a standard timeline, the Company would anticipate a
        determination by the EMA in mid-2015.
     -- The Company's Japanese partner, Japan Tobacco Inc. and Torii
        Pharmaceutical (JT/Torii), received manufacturing and marketing approval
        of ferric citrate in Japan for the improvement of hyperphosphatemia in
        patients with CKD, including both dialysis and non-dialysis dependent
        CKD. The Japanese launch is planned for May 12, 2014, where it will be
        marketed as Riona(r). Keryx will receive royalties on net sales of Riona
        in Japan.
  -- During the quarter, Keryx also made progress on the further clinical
     development of Zerenex. The Company has substantially finalized the trial
     design for a phase 3 study to evaluate Zerenex for the treatment of iron
     deficiency anemia in non-dialysis dependent CKD patients. Keryx plans to
     initiate the phase 3 trial in the third quarter of 2014.

First Quarter Ended March 31, 2014 Financial Results

At March 31, 2014, the Company had cash, cash equivalents, short-term
investments and interest receivable of $155.1 million, as compared to $55.7
million at December 31, 2013. In January 2014, the Company completed an
underwritten public offering of common stock, which provided proceeds to the
Company of approximately $107.6 million, net of underwriting discounts and
offering expenses of approximately $7.5 million. In February 2014, the Company
received a $10.0 million milestone payment from its Japanese partner for
Zerenex, JT/Torii, related to the manufacturing and marketing approval of
ferric citrate in Japan in January 2014. 

The net loss for the first quarter ended March 31, 2014 was $13.5 million, or
$0.15 per share, compared to a net loss of $2.1 million, or $0.03 per share,
for the comparable quarter in 2013, representing an increase in net loss of
$11.4 million. In January 2014, the Company recorded license revenue of $10.0
million for the milestone payment received from its Japanese partner for
Zerenex, JT & Torii, as discussed above. For the first quarter ended March 31,
2014, other research and development expenses increased by $9.3 million, as
compared to the first quarter of 2013, related to the Company's Zerenex
program, including costs associated with the manufacturing of pre-launch
inventory and capacity expansion and preparation and submission of its MAA to
the EMA.  The three months ended March 31, 2014, also includes a $2.0 million
one-time milestone payment to the licensor of Zerenex, related to JT/Torii's
achievement of the Japanese marketing approval milestone in January 2014. Other
general and administrative expenses during the first quarter of 2014 increased
by $3.2 million, as compared to the first quarter of 2013, primarily related to
pre-commercial activities related to Zerenex. The net loss for the first
quarter ended March 31, 2014, included $2.6 million of non-cash compensation
expense related to equity incentive grants. 

Conference Call Information

Keryx will host an investor conference call today, Thursday, May 8, 2014, at
8:00am ET to discuss the Company's first quarter 2014 financial results and
provide a business outlook for the remainder of 2014. 

In order to participate in the conference call, please call 1-877-869-3847
(U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio
recording of the conference call will be available for replay at
http://www.keryx.com, for a period of 15 days after the call. 

                         Keryx Biopharmaceuticals, Inc.                         
                      Selected Consolidated Financial Data                      
               (In Thousands, Except Share and Per Share Amounts)               
                                                                                
Statements of Operations Information (Unaudited):                               
                                                                                
                                                       Three Months Ended March 
                                                                 31,            
                                                     ---------------------------
                                                         2014           2013    
                                                     ---------------------------
                                                                                
REVENUE:                                                                        
License revenue                                           $10,000         $7,000
                                                     ---------------------------
                                                                                
OPERATING EXPENSES:                                                             
Research and development:                                                       
 Non-cash compensation                                        804            191
 Other research and development                            15,555          6,239
                                                     ---------------------------
   Total research and development                          16,359          6,430
                                                     ---------------------------
                                                                                
General and administrative:                                                     
 Non-cash compensation                                      1,748            390
 Other general and administrative                           5,544          2,338
                                                     ---------------------------
   Total general and administrative                         7,292          2,728
                                                     ---------------------------
                                                                                
TOTAL OPERATING EXPENSES                                   23,651          9,158
                                                     ---------------------------
                                                                                
OPERATING LOSS                                           (13,651)        (2,158)
                                                                                
OTHER INCOME:                                                                   
Interest and other income, net                                121            103
                                                     ---------------------------
                                                                                
NET LOSS                                               $ (13,530)      $ (2,055)
                                                     ===========================
                                                                                
NET LOSS PER COMMON SHARE                                                       
Basic and diluted net loss per common share               $(0.15)        $(0.03)
                                                     ===========================
                                                                                
SHARES USED IN COMPUTING NET LOSS                                               
PER COMMON SHARE                                                                
Basic and diluted                                      88,517,437     77,990,094
                                                     ===========================
                                                                                
Balance Sheet Information:                                                      
                                                       March 31,    December 31,
                                                         2014          2013*    
                                                     ---------------------------
                                                      (unaudited)               
Cash, cash equivalents, interest receivable, and         $155,117        $55,696
 short-term investment securities                                               
Total assets                                             $160,325        $60,766
Accumulated deficit                                   $ (452,870)    $ (439,340)
Stockholders' equity                                     $143,915        $45,400
                                                                                
* Condensed from audited financial statements.                                  

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing
innovative therapies to market for patients suffering from renal disease. In
the United States, ferric citrate coordination complex is currently under
review by the Food and Drug Administration (FDA) for the treatment of
hyperphosphatemia in dialysis-dependent chronic kidney disease (CKD) patients,
where, pending approval, it will be marketed as Zerenex(tm) by Keryx. In January
2014, ferric citrate was approved for the treatment of patients with all stages
of CKD in Japan, where it will be marketed as Riona(r) by Keryx's Japanese
partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. 

About Zerenex(tm)

Zerenex(tm) (ferric citrate coordination complex), is an oral, ferric iron-based
phosphate binder. Keryx has completed a U.S.-based phase 3 clinical program for
Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in
dialysis-dependent CKD patients, conducted pursuant to a Special Protocol
Assessment (SPA) agreement with the FDA. The Company's New Drug Application
(NDA) is currently under review by the FDA with an assigned Prescription Drug
User Fee Act (PDUFA) goal date of June 7, 2014. Keryx has filed a Marketing
Authorization Application (MAA) with the European Medicines Agency (EMA),
seeking the approval of Zerenex as a treatment of hyperphosphatemia in patients
with all stages of CKD and that application is currently under review. 

Cautionary Statement

Some of the statements included in this press release, particularly those
relating to the results of clinical trials, the potential clinical benefits to
be derived from Zerenex, regulatory submissions and approvals, the potential
commercial opportunity and competitive positioning, and any business prospects
for Zerenex, may be forward-looking statements that involve a number of risks
and uncertainties. For those statements, we claim the protection of the safe
harbor for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Among the factors that could cause our actual
results to differ materially are the following: acceptance of the NDA filing
represents only a preliminary evaluation of the application and is not
indicative of deficiencies that may be identified during the FDA's review; a
PDUFA goal date is subject to change and does not guarantee that the review of
the NDA will be completed on a timely basis; the risk that the FDA, and/or EMA
ultimately deny approval of the U.S. NDA, and/or MAA, respectively; the risk
that SPAs are not a guarantee that the FDA will ultimately approve a product
candidate following filing acceptance; whether the FDA and EMA will concur with
our interpretation of our Phase 3 study results, supportive data, or the
conduct of the studies; whether Riona(r) will be successfully launched and
marketed by our Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical
Co., Ltd.; whether, Zerenex, if approved by the FDA and/or EMA, will be
successfully launched and marketed; and other risk factors identified from time
to time in our reports filed with the Securities and Exchange Commission. Any
forward-looking statements set forth in this press release speak only as of the
date of this press release. We do not undertake to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. This press release and prior releases are available at
http://www.keryx.com. The information found on our website is not incorporated
by reference into this press release and is included for reference purposes
only. 


         CONTACT: KERYX CONTACT:
         Amy Sullivan, Vice President, Corporate Development and
         Public Affairs
         Tel: 508.479.3480 - e-mail: amy.sullivan@keryx.com
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

08.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                         
Company:     Keryx Biopharmaceuticals, Inc.  
 
 
             United States                   
ISIN:        US4925151015                    
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
267292 08.05.2014